We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Graft Polymer (uk) Plc | LSE:GPL | London | Ordinary Share | GB00BMD1Z199 | ORD GBP0.001 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.015 | 7.32% | 0.22 | 194,724,431 | 16:17:38 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.21 | 0.23 | 0.235 | 0.19 | 0.205 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Business Services, Nec | 45.63M | -2.52M | -0.0202 | -0.11 | 255.77k |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:29:56 | O | 3,000,000 | 0.2175 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 23/7/2024 | 16:46 | ALNC |  EARNINGS AND TRADING: James Cropper posts loss; Arbuthnot profit falls |
| 23/7/2024 | 13:59 | UK RNS | Graft Polymer (UK) PLC Holding(s) in Company |
| 23/7/2024 | 07:00 | UK RNS | Graft Polymer (UK) PLC Commercial Collaboration |
| 18/7/2024 | 07:00 | UK RNS | Graft Polymer (UK) PLC Commercial Collaboration |
| 17/7/2024 | 09:28 | UK RNS | Graft Polymer (UK) PLC Holding(s) in Company |
| 15/7/2024 | 07:00 | UK RNS | Graft Polymer (UK) PLC Directorate Change |
| 12/7/2024 | 07:00 | UK RNS | Graft Polymer (UK) PLC Holding(s) in Company |
| 12/7/2024 | 07:00 | UK RNS | Graft Polymer (UK) PLC Holding(s) in Company |
| 11/7/2024 | 16:42 | ALNC | IN BRIEF: Graft Polymer files US patent applications as raises equity |
| 11/7/2024 | 09:36 | UK RNS | Graft Polymer (UK) PLC Holding(s) in Company |
Graft Polymer (uk) (GPL) Share Charts1 Year Graft Polymer (uk) Chart |
|
1 Month Graft Polymer (uk) Chart |
Intraday Graft Polymer (uk) Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 26/7/2024 | 11:20 | Grafting Graft Polymer | 581 |
| 16/7/2024 | 07:23 | Beware of this scam | 20 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-07-26 15:35:02 | 0.22 | 3,000,000 | 6,525.00 | O |
| 2024-07-26 15:29:57 | 0.22 | 147,908 | 322.44 | O |
| 2024-07-26 15:26:53 | 0.22 | 543,904 | 1,190.06 | O |
| 2024-07-26 15:26:53 | 0.21 | 1,971,871 | 4,160.65 | O |
| 2024-07-26 15:26:41 | 0.21 | 843,168 | 1,779.08 | O |
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Graft Polymer (uk) Daily Update Graft Polymer (uk) Plc is listed in the Business Services, Nec sector of the London Stock Exchange with ticker GPL. The last closing price for Graft Polymer (uk) was 0.21p.Graft Polymer (uk) currently has 124,763,966 shares in issue. The market capitalisation of Graft Polymer (uk) is £274,481. Graft Polymer (uk) has a price to earnings ratio (PE ratio) of -0.11. This morning GPL shares opened at 0.21p |
Posted at 23/7/2024 20:38 by ssrover All of awakn lead compoundsAre novel and inventive. They carried out the HtL And the lead compounds are both novel and inventive and Gpl are in for 40% of any revenues. About Awakn’s Aminoindane NCEs Aminoindanes are a class of molecules that offer an alternative source of medical empathogens to MDMA for use alongside psycho-social support in the treatment of trauma related mental health disorders. Aminoindanes have similar pharmacological properties to MDMA, they promote serotonin dopamine and noradrenaline release and block their reuptake. This combination of effects is believed to underpin the empathogenic activity. They offer a novel patentable approach to the treatment of trauma-related disorders. Awakn acquired six years of proprietary research data from Prof. David Nutt, this data described potentially fast acting aminoindane compounds Awakn has completed a Hit to Lead (HtL) program with Evotec. In vitro and in vivo data shows efficacy for drug-like hits, defining chemical series for lead optimization. Awakn has filed patents for two promising chemical series identified for lead optimization |
Posted at 18/7/2024 08:10 by kingston78 An initial mark up has turned into a mark down. If the company receives money now from a third party for the collaboration the share price will be up. But the reverse is happening. The company is paying a third party £300k to study something. That may be money down the drain. |
Posted at 12/7/2024 08:37 by tomboyb The GPL SHOW -Sticky sticky sticky - |
Posted at 11/7/2024 10:42 by ssrover GPL reminds me of #CPX .. volume insane at #GPL.. directors buying, myles buying, orien taking 9%.. see this multibagging short |
Posted at 09/7/2024 09:45 by citys2874 GPL just had a bounce up CORA set to fly next worth a look |
Posted at 09/7/2024 08:39 by citys2874 Good start this morning for GPL and CORA ......CORA may bag today should be a great day for both |
Posted at 03/7/2024 16:20 by bozzy_s Easy profit? For those who bought at 0.1p perhaps. But I wouldn't call it easy. It's 20% for now, for a tiny number of shares.The shares are worth 0.1p - that's what the company has valued itself at. This premium share price won't stay for long (currently 0.12-0.15 spread, so asking buyers to pay a 50% premium vs almost all the other shareholders. Why would anyone in their right mind do that?). Always seems to be the case when a company utterly screws its shareholders in a placing, they 'forget' to include the line 'the placing price represents a discount of xx% to the latest closing price'. |
Posted at 02/7/2024 14:07 by dillydally2 Not one single tweet on X about GPLOnly a few nonces on lse and a couple of idiots here |
Posted at 02/7/2024 13:42 by dillydally2 GPL lse site getting over excited on nothing A few pumpers now claiming all sorts It's quite astonishing the level of greed This company is 10m mcap and overvalued |
Posted at 04/6/2024 16:02 by stealive The only thing that is up is the share price. (Drops mic) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
